Filtering by:
Liver CancerFacts & Figures 2021 Reports Another Record-Breaking 1-Year Drop in Cancer Deaths
The death rate from cancer in the United States has continued to decline. From 1991 to 2018, the cancer death rate has fallen 31%. This includes a 2.4% decline from 2017 to 2018—a new record for the largest 1-year drop in the cancer death rate. These are just some of the findings from the annual statistics reported from the American Cancer Society (ACS).
Study: Getting Enough Exercise Lowers Risk of 7 Cancers
Getting recommended amounts of physical activity is linked to a lower risk for 7 cancer types, according to a study from the American Cancer Society, the National Cancer Institute, and the Harvard T.H. Chan School of Public Health.
Death Rates from Liver Cancer Are Increasing, Especially in Men with Less Education
Liver cancer is the fastest growing cause of cancer death in the United States, and the increase is mainly among adults who have less education, especially men, according to a new study by American Cancer Society (ACS). The study was led by Jiemin Ma, PhD, MHS, and published online April 8, 2019 in Cancer, a peer-reviewed journal of the ACS.
Study Ties Whole Grains to Lower Risk of Liver Cancer
A large observational study shows eating more whole-grain foods may be linked to a lower risk of getting liver cancer.
Facts & Figures 2019: US Cancer Death Rate has Dropped 27% in 25 Years
The death rate from cancer in the US has declined steadily over the past 25 years, according to annual statistics reporting from the American Cancer Society.
Facts & Figures 2018: Rate of Deaths From Cancer Continues Decline
The death rate from cancer in the US has declined steadily over the past 2 decades, according to annual statistics reporting from the American Cancer Society.
FDA Approves Opdivo (Nivolumab) for Liver Cancer
The US Food and Drug Administration (FDA) has approved Opdivo (nivolumab), a monoclonal antibody, which is a type of immunotherapy, to treat liver cancer.
FDA Approves Stivarga (Regorafenib) for Liver Cancer
The US Food and Drug Administration (FDA) has expanded the approved use of the targeted therapy drug Stivarga (regorafenib) to treat liver cancer.